ClinicalTrials.gg
TerminatedNCT04596995myOpportunITy3Updated Feb 5, 2024Results posted

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

A Phase 3 interventional study of Rozanolixizumab in Primary Immune Thrombocytopenia, sponsored by UCB Biopharma SRL. Terminated at 27 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Strategic Business Decision; Not a safety decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine — 1 open to participants now, 1 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Ukraine.

Enrollment
10th of 16
43 · median 54
Started
2021
with 1 other
Phase 3
12 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
3 of 16
UCB Biopharma SRL

Among the 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 12 in phase 3, and was the 14th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

1 of the 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine is open now. Recruiting first, the newest first:

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • ITP
  • UCB7665
  • Rozanolixizumab
  • Primary immune thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant completed TP0003 [NCT04200456] or TP0006 [NCT04224688] until Visit 27 (Week 25) and, in the opinion of the investigator, has been compliant with the TP0003 or TP0006 study assessments
  • The study participant is considered reliable and capable of adhering to the protocol, visit schedule, or medication intake according to the judgment of the investigator
  • Study participants may be male or female:

    1. A male participant must agree to use during the Treatment Period and for at least 3 months after the final dose of study treatment and refrain from donating sperm during this period
    2. A female participant is eligible to participate if she is not pregnant as confirmed by a negative urine pregnancy test and not planning to get pregnant during the participation in the study, not breastfeeding, and at least one of the following conditions applies:

Not a woman of (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 3 months after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Study participant has any ongoing medicinal product (IMP)-related serious adverse event (SAE) or ongoing severe IMP-related treatment-emergent adverse event (TEAE) experienced during TP0003 or TP0006
  • Study participant has, at last available assessment of TP0003 or TP0006, 3.0x (ULN) of any of the following: (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab Treatment Arm

    All study participants will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.

    Drug: Rozanolixizumab

Interventions

  • Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.

    Also known as: UCB7665

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

    Time frame: From Baseline to end of Safety Follow-Up Period (up to Week 60)

  2. Percentage of Participants With TEAEs Leading to Permanent Withdrawal of Rozanolixizumab (ie, Study Discontinuation)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

    Time frame: From Baseline to end of Safety Follow-Up Period (up to Week 60)

Secondary outcomes

  1. Percentage of Participants With Stable Clinically Meaningful Response Without Rescue Therapy at ≥70% of the Visits Over the Planned 52-week Treatment Period Starting at Week 4

    Stable Clinically Meaningful Response was defined as Clinically Meaningful Response (ie, platelet count ≥50×10\^9/L) without rescue therapy at ≥70% of the visits over the planned 52-week Treatment Period starting at Week 4.

    Time frame: Over the 52-week Treatment Period (starting at Week 4)

  2. Change From Baseline in Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) to Week 53 or 55 Symptoms Domain Score

    The ITP-PAQ Version 1 is a 44 item disease-specific Health-Related Quality of Life questionnaire developed for use in adults with chronic ITP. It includes 10 scales, Four of the scales measure physical health: Symptoms (6 items), Bother (3 items), Fatigue (4 items), and Activity (2 items). Two of the scales measure emotional health: Fear (5 items) and Psychological (5 items) Health. The remaining four scales measure other aspects of quality of life (QOL): Work QOL (4 items), Social QOL (4 items), Women's Reproductive QOL (6 items) and Overall QOL (5 items). Each item is rated on a Likert-type scale containing 4 to 7 responses. All item scores are transformed to a 0 to 100 continuum and are weighted equally to derive individual scale scores and the total score (0-100) is calculated as per the formula: Sum of item scores within the scale/raw sum range\*100. Higher scores indicate better health status.

    Time frame: Week 53 or 55, compared to Baseline

07

Results

Posted Feb 5, 2024

Participant flow

The study started to enroll study participants in January 2021 and completed prematurely in December 2022. Study participants from TP0003 (NCT04200456) or TP0006 (NCT04224688) who had completed the 24-week Treatment Period (irrespective of rescue therapy) and met eligibility criteria for TP0004 were enrolled in this study.

Participant flow — Overall Study
MilestoneRozanolixizumab
Started43
Completed14
Not completed29
Withdrew: Lack of efficacy8
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject12
Withdrew: Sponsor decision3
Withdrew: Enrolled in managed access program3

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

Time frame:
From Baseline to end of Safety Follow-Up Period (up to Week 60)
Reported as:
Number · percentage of Participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of ParticipantsRozanolixizumab
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)90.7
PrimaryPercentage of Participants With TEAEs Leading to Permanent Withdrawal of Rozanolixizumab (ie, Study Discontinuation)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

Time frame:
From Baseline to end of Safety Follow-Up Period (up to Week 60)
Reported as:
Number · percentage of Participants
Percentage of Participants With TEAEs Leading to Permanent Withdrawal of Rozanolixizumab (ie, Study Discontinuation)
percentage of ParticipantsRozanolixizumab
Percentage of Participants With TEAEs Leading to Permanent Withdrawal of Rozanolixizumab (ie, Study Discontinuation)0
SecondaryPercentage of Participants With Stable Clinically Meaningful Response Without Rescue Therapy at ≥70% of the Visits Over the Planned 52-week Treatment Period Starting at Week 4

Stable Clinically Meaningful Response was defined as Clinically Meaningful Response (ie, platelet count ≥50×10\^9/L) without rescue therapy at ≥70% of the visits over the planned 52-week Treatment Period starting at Week 4.

Time frame:
Over the 52-week Treatment Period (starting at Week 4)
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Clinically Meaningful Response Without Rescue Therapy at ≥70% of the Visits Over the Planned 52-week Treatment Period Starting at Week 4
percentage of participantsRozanolixizumab
Percentage of Participants With Stable Clinically Meaningful Response Without Rescue Therapy at ≥70% of the Visits Over the Planned 52-week Treatment Period Starting at Week 416.3
SecondaryChange From Baseline in Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) to Week 53 or 55 Symptoms Domain Score

The ITP-PAQ Version 1 is a 44 item disease-specific Health-Related Quality of Life questionnaire developed for use in adults with chronic ITP. It includes 10 scales, Four of the scales measure physical health: Symptoms (6 items), Bother (3 items), Fatigue (4 items), and Activity (2 items). Two of the scales measure emotional health: Fear (5 items) and Psychological (5 items) Health. The remaining four scales measure other aspects of quality of life (QOL): Work QOL (4 items), Social QOL (4 items), Women's Reproductive QOL (6 items) and Overall QOL (5 items). Each item is rated on a Likert-type scale containing 4 to 7 responses. All item scores are transformed to a 0 to 100 continuum and are weighted equally to derive individual scale scores and the total score (0-100) is calculated as per the formula: Sum of item scores within the scale/raw sum range\*100. Higher scores indicate better health status.

Time frame:
Week 53 or 55, compared to Baseline
Reported as:
Mean · score on a scale
Change From Baseline in Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) to Week 53 or 55 Symptoms Domain Score
score on a scaleRozanolixizumab
Week 532.98 ± 11.21
Week 554.17 ± 12.50

Adverse events

Collected over From Baseline to end of Safety Follow-Up Period (up to Week 60). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rozanolixizumab0/43 (0%)9/43 (20.9%)31/43 (72.1%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventRozanolixizumab
COVID-19Infections and infestations2/43
Uterine haemorrhageReproductive system and breast disorders2/43
Immune thrombocytopeniaBlood and lymphatic system disorders1/43
PyrexiaGeneral disorders1/43
Joint dislocationInjury, poisoning and procedural complications1/43
Radius fractureInjury, poisoning and procedural complications1/43
Platelet count decreasedInvestigations1/43
LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/43
PurpuraSkin and subcutaneous tissue disorders1/43
Skin haemorrhageSkin and subcutaneous tissue disorders1/43
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRozanolixizumab
HeadacheNervous system disorders18/43
PyrexiaGeneral disorders9/43
COVID-19Infections and infestations7/43
DiarrhoeaGastrointestinal disorders5/43
NauseaGastrointestinal disorders5/43
FatigueGeneral disorders5/43
Body temperature increasedInvestigations5/43
PharyngitisInfections and infestations4/43
AnaemiaBlood and lymphatic system disorders3/43
VomitingGastrointestinal disorders3/43

Baseline characteristics

Baseline Characteristics refer to Enrolled Set which consisted of all study participants who signed the informed consent form (ICF).

Age, Continuous
Age, Continuous(years)Rozanolixizumab
Mean42.7 ± 13.7
Age, Customized
Age, Customized(Participants)Rozanolixizumab
18 - <65 years41
>=65 - <85 years2
>=85 years0
Sex: Female, Male
Sex: Female, Male(Participants)Rozanolixizumab
Female28
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rozanolixizumab
Asian8
White33
Other or Mixed1
Missing1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rozanolixizumab
Hispanic or Latino2
Not Hispanic or Latino41
08

Study locations

27 sites
  • Tp0004 50243
    Boston, Massachusetts 02114, United States
  • Tp0004 20179
    Fuzhou, China
  • Tp0004 20185
    Jinan, China
  • Tp0004 20194
    Wuxi, China
  • Tp0004 20050
    Tbilisi, Georgia
  • Tp0004 40369
    Berlin, Germany
  • Tp0004 40202
    Győr, Hungary
  • Tp0004 40178
    Nyíregyháza, Hungary
  • Tp0004 40208
    Firenze, Italy
  • Tp0004 20039
    Iruma-gun, Japan
  • Tp0004 20051
    Chisinau, Moldova, Republic of
  • Tp0004 40218
    Gdansk, Poland
  • Tp0004 40222
    Skorzewo, Poland
  • Tp0004 40219
    Slupsk, Poland
  • Tp0004 40223
    Warszawa, Poland
  • Tp0004 20052
    Moscow, Russian Federation
  • Tp0004 20053
    Saint Petersburg, Russian Federation
  • Tp0004 40268
    Madrid, Spain
  • Tp0004 20095
    Taipei City, Taiwan
  • Tp0004 20099
    Taipei, Taiwan
  • Tp0004 20061
    Cherkasy, Ukraine
  • Tp0004 20060
    Dnipropetrovsk, Ukraine
  • Tp0004 20062
    Ivano-frankivsk, Ukraine
  • Tp0004 20063
    Kyiv, Ukraine
  • Tp0004 20064
    Kyiv, Ukraine
  • Tp0004 20100
    Zaporizhzhia, Ukraine
  • Tp0004 40234
    Plymouth, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Dec 2022, 23 months.

Results were first posted in Feb 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2020
First posted
Oct 22, 2020
StartActual
Jan 6, 2021
Primary completionActual
Dec 21, 2022
CompletionActual
Dec 21, 2022
Results first posted
Feb 5, 2024
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04596995
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Oct 22, 2020
Start date
Jan 6, 2021
Primary completion
Dec 21, 2022
Completion
Dec 21, 2022
Results posted
Feb 5, 2024
Last update
Feb 5, 2024

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion